)
Visual
earnings real time
Lipella Pharmaceuticals
Lipella Pharmaceuticals (LIPO) investor relations material
Lipella Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Focused on developing reformulated generic drugs for new indications, with lead programs LP-10 (hemorrhagic cystitis) and LP-310 (oral lichen planus) in clinical development; LP-410 (oral GVHD) and LP-50 (bladder cancer) in earlier stages.
No commercialized products; revenue derived from NIH grants, which expired in June 2025.
Announced completion of LP-310 Phase 2a trial in Q3 2025, with positive safety and tolerability data.
Chief Medical Officer announced retirement effective December 2025.
Financial highlights
Revenue for Q3 2025 was $0, down from $80,380 in Q3 2024 due to grant expiration.
Net loss for Q3 2025 was $1.25M, improved from $1.44M in Q3 2024; net loss for nine months ended September 30, 2025 was $3.89M, up from $3.57M in 2024.
R&D expenses for Q3 2025 were $721K, down $326K year-over-year, mainly due to lower stock option expense.
General and administrative expenses for Q3 2025 were $552K, up $60K year-over-year, driven by higher professional and outside services.
Cash and cash equivalents at September 30, 2025 were $1.86M.
Outlook and guidance
Existing cash expected to fund operations through the end of 2025, but additional capital will be required for continued development.
Anticipates continued operating losses and negative cash flows due to ongoing R&D and clinical activities.
What is the impact of OTC trading on capital?
Detail plans to address going concern beyond 2025
How will LP-310 Phase 2a results guide R&D spend?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- TQ5
Recurring income and capital recycling offset lower residential profits, supporting stable dividends. - DSV
Schenker integration and strong 2025 results set up 2026 EBIT guidance at DKK 23–25.5bn. - 8473
Record profit and revenue growth, with annualized ROE at 29.9% and robust segment results. - BSX
Double-digit sales and EPS growth in 2025, with strong Cardiovascular and MedSurg performance. - LEA
2025 saw record sales and margins, with 2026 guidance targeting up to $24B sales and strong cash flow. - KMT
Q2 sales and earnings surged, prompting raised full-year guidance and a dividend declaration. - COR
Q1 revenue up 5.5% to $85.9B, adjusted EPS up 9.4%, and guidance raised after OneOncology deal. - METROPOLIS
Strong profit growth, bonus share issue, and strategic acquisitions mark the quarter. - EFX
Q4 2025 revenue up 9% and 2026 guidance targets 10.5% revenue growth and 11% EPS growth. - CTSH
Revenue, margin, and EPS grew year-over-year, with strong bookings and positive 2026 outlook.
Next Lipella Pharmaceuticals earnings date
Q4 202527 Mar, 2026
Lipella Pharmaceuticals
Next Lipella Pharmaceuticals earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Lipella Pharmaceuticals Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for urologic and other rare diseases. The company specializes in the reformulation and delivery of existing drugs using proprietary technology to treat conditions such as interstitial cystitis, hemorrhagic cystitis, and other bladder-related disorders. Lipella conducts research and clinical trials to advance its drug candidates through regulatory pathways. The company is headquartered in Pittsburgh, Pennsylvania, and its shares are listed on the CSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage